UNSPSC 51263165: Levobunolol hydrochloride

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C17H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O90S49LDHH, chemically known as 1(2h)-naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, hydrochloride, (-)- but more generally known as levobunolol hydrochloride, which bears US NIH Compound Identifier 34060.

UNSPSC 51263165 Levobunolol hydrochloride is a Commodity code nominally identifying a specific ophthalmic beta-blocker medication, but recent state and local opportunities tagged under this code show no procurement activity for levobunolol itself. Instead, the code appears in solicitations for unrelated pharmaceutical and health-services products — naloxone (an opioid-reversal agent) and drug deactivation systems — suggesting a potential tagging misalignment in the source databases. State and local health departments and human services agencies issuing under this code are seeking to procure pharmaceutical supplies and pharmacy-benefit management services, including medication procurement, direct-to-manufacturer prescription programs, and community health support products. The issuing-body mix includes county health services (Seminole County, Florida) and state health and human services commissions (Texas Health and Human Services Commission), reflecting activity concentrated in public health and pharmacy-benefit administration rather than traditional pharmaceutical supply chains.

Geographic activity appears limited to Florida and Texas based on recent postings. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, requiring electronic bid submission and E-Verify compliance. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, soliciting information on direct contracting between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager arrangements. No other state or local jurisdictions appear in recent opportunity records under this code.